In a recent study published in the CMJA, the evidence supporting the use of gabapentin, pregabalin and topiramate for low back pain and lumbar radicular pain. Based upon self-reported efficacy, disability and adverse effects, the evidence supporting the use of these products was unconvincing. This is disconcerting given the rise of the use of these agents (especially as the availability of opioids tightens), and the increasing concerns about adverse effects (including dependence and withdrawal phenomena).